AUS
NZ
UK
CA
USA
IND
Highlights
- Arcus Biosciences uses the Discounted Cash Flow.
- The company’s estimated equity value stands at US$1.7 billion based on future cash.
- The stock appears fairly priced with a 1.6% discount relative to its current trading value.
Arcus Biosciences Inc. presents an intriguing case when evaluating the intrinsic value of healthcare stocks. Using the Discounted Cash Flow (DCF) model, the company’s future cash flows are analyzed to estimate its fair value. This method helps shed light on whether Arcus Biosciences is aligned with market expectations and provides insights into its valuation within NYSE Healthcare Stocks.
Estimating the Intrinsic Value of Arcus Biosciences, Inc. (NYSE:RCUS)
Valuing a company like Arcus Biosciences, Inc. involves a detailed financial approach, particularly using models such as the Discounted Cash Flow (DCF) method. This model helps determine whether the stock is fairly priced by calculating its future cash flows and discounting them to their present value.
The Two-Stage Growth Model
Arcus Biosciences' intrinsic value is derived using the two-stage growth model, which accounts for two distinct growth periods: an initial high-growth phase and a subsequent stable growth phase. The model estimates the company's future cash flows for the next ten years and uses those to calculate its terminal value. This is done by assuming a conservative growth rate after the high-growth period, one that aligns with a country's GDP growth rate (2.6%).
Discounting Future Cash Flows
To calculate the present value of these future cash flows, a discount rate of 6.3% is applied. This rate is based on Arcus' cost of equity, which is determined using the company’s levered beta (a measure of the stock's volatility). The DCF model estimates the total equity value at US$1.7 billion, which is then divided by the number of shares outstanding to arrive at the intrinsic value per share.
Comparing the Intrinsic Value to the Market Price
When comparing the intrinsic value with the current market price, Arcus Biosciences appears to be fairly priced, with a slight 1.6% discount to the market value. While this may suggest the stock is near its fair value, it's important to recognize that valuations are imprecise, and small changes in assumptions can lead to significant differences in the results.
Key Insights
Though the DCF model offers a useful framework for valuing Arcus Biosciences, there are limitations to consider. It does not account for factors like industry cyclicality or future capital needs, and adjustments to the assumptions can lead to substantial changes in the valuation. Investors should use the DCF model as a guide and supplement it with other analyses when evaluating a stock's potential performance.
By looking at these key elements, shareholders can gain a better understanding of the underlying value of Arcus Biosciences and how it compares to current market trends.
